Estudo randomizado | Apatinibe melhora os desfechos em comparação ao placebo em pacientes com câncer de tireoide diferenciado localmente avançado ou metastático e refratário a radiação com iodo.

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial – JAMA Oncology

Comentário no Twitter

Apatinib offered significant clinical benefits in terms of both prolonged progression-free survival and overall survival in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. https://t.co/I14AyxKZNS

— JAMA Oncology (@JAMAOnc) December 16, 2021